Literature DB >> 29027036

Risk factors of ceftriaxone-associated biliary pseudolithiasis in adults: influence of renal dysfunction.

Aya Imafuku1, Naoki Sawa2,3, Akinari Sekine2, Masahiro Kawada2, Rikako Hiramatsu2, Masayuki Yamanouchi2, Eiko Hasegawa2, Noriko Hayami2, Jyunichi Hoshino2, Yoshifumi Ubara2, Kenmei Takaichi2.   

Abstract

BACKGROUND: Ceftriaxone (CTRX) is a known cause of biliary pseudolithiasis (BPL) mainly in children. Biliary elimination of CTRX increases in patients with renal dysfunction. However, the influence of renal dysfunction on the incidence of CTRX-associated BPL has not been well investigated. The aim of this study was to investigate the cumulative incidence of CTRX-associated BPL in adults and to assess if renal dysfunction is a risk factor.
METHODS: We retrospectively analyzed the medical records of 478 patients treated with CTRX to assess the incidence and risk factors of CTRX-associated BPL. We examined age, sex, body weight, dosage, and duration of CTRX therapy, and the concentrations of serum creatinine, estimated glomerular filtration rate (eGFR), albumin, and serum calcium in all the patients. The cumulative incidence of BPL was calculated using a competing risk model. The multivariate analysis of each variable for the development of BPL was assessed by a Cox proportional hazards model.
RESULTS: A total of 362 patients (75.7%) had renal dysfunction (eGFR: < 60 mL/min). The cumulative incidence of BPL in patients with renal dysfunction was significantly higher than that in patients with normal kidney function (4.1 vs. 0.6%, p = 0.017). Renal dysfunction (Hazard ratio (HR) 8.14, 95% CI 1.05-63.0, p = 0.045) and female sex (HR 5.35, 95% CI 1.17-24.5, p = 0.031) were independent risk factors of CTRX-associated BPL, which was confirmed using multivariate analysis (renal dysfunction: HR 7.93, 95% CI 1.04-60.5, p = 0.046) (female sex HR 4.65, 95% CI 1.03-21.1, p = 0.046).
CONCLUSIONS: Renal dysfunction is an independent risk factor of CTRX-associated BPL in adults.

Entities:  

Keywords:  Ceftriaxone-associated biliary pseudolithiasis; Infection; Kidney dysfunction

Mesh:

Substances:

Year:  2017        PMID: 29027036     DOI: 10.1007/s10157-017-1493-7

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  27 in total

1.  Reversible ceftriaxone-associated biliary pseudolithiasis in children.

Authors:  U B Schaad; J Wedgwood-Krucko; H Tschaeppeler
Journal:  Lancet       Date:  1988-12-17       Impact factor: 79.321

2.  Incidence of gallbladder lithiasis after ceftriaxone treatment.

Authors:  A Cometta; S Gallot-Lavallée-Villars; A Iten; L Cantoni; A Anderegg; J J Gonvers; M P Glauser
Journal:  J Antimicrob Chemother       Date:  1990-04       Impact factor: 5.790

3.  Incidence of ceftriaxone-associated gallbladder pseudolithiasis.

Authors:  F Papadopoulou; S Efremidis; S Karyda; M Badouraki; E Karatza; C Panteliadis; K Malaka
Journal:  Acta Paediatr       Date:  1999-12       Impact factor: 2.299

4.  Transient formation of precipitations in the gallbladder associated with ceftriaxone therapy.

Authors:  U B Schaad; H Tschäppeler; M J Lentze
Journal:  Pediatr Infect Dis       Date:  1986 Nov-Dec

5.  A comparison of ceftriaxone and cefuroxime for the treatment of bacterial meningitis in children.

Authors:  U B Schaad; S Suter; A Gianella-Borradori; J Pfenninger; R Auckenthaler; O Bernath; J J Cheseaux; J Wedgwood
Journal:  N Engl J Med       Date:  1990-01-18       Impact factor: 91.245

6.  Pathogenesis of ceftriaxone-associated biliary sludge. In vitro studies of calcium-ceftriaxone binding and solubility.

Authors:  M L Shiffman; F B Keith; E W Moore
Journal:  Gastroenterology       Date:  1990-12       Impact factor: 22.682

7.  Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis.

Authors:  D Cohen; G B Appel; B Scully; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1983-10       Impact factor: 5.191

Review 8.  Ceftriaxone. A review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  D M Richards; R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-06       Impact factor: 9.546

9.  Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model.

Authors:  K Stoeckel; J R Koup
Journal:  Am J Med       Date:  1984-10-19       Impact factor: 4.965

10.  Biliary precipitation during ceftriaxone therapy: frequency and risk factors.

Authors:  Ahmet Soysal; Kemal Eraşov; Ihsan Akpinar; Mustafa Bakir
Journal:  Turk J Pediatr       Date:  2007 Oct-Dec       Impact factor: 0.552

View more
  6 in total

1.  Rapid formation of large pseudostones and acute cholangitis caused by ceftriaxone treatment for bacterial pneumonia in a patient on kidney transplantation: potential risk of ceftriaxone use in patients with decreased kidney function.

Authors:  Shunsuke Yamada; Manako Takesako; Toshiaki Nakano; Kazuhiko Tsuruya; Takanari Kitazono
Journal:  CEN Case Rep       Date:  2019-09-17

2.  Ceftriaxone-Induced Pancreatitis.

Authors:  Muneerah M Albugami; Mohamed Ahmed; Abdulelah Bin Shihah
Journal:  Can J Hosp Pharm       Date:  2021-07-01

3.  Acute necrotizing calculous cholecystitis after treatment with ceftriaxone in an elderly patient: a case report.

Authors:  Tsunehiko Shigemori; Ichiro Imoto; Yasuhiro Inoue; Ryo Nishiwaki; Natsuko Sugimasa; Tetsuya Hamaguchi; Midori Noji; Kenji Takeuchi; Yoshiyuki Ito; Taro Yasuma; Esteban C Gabazza; Toshio Kato
Journal:  Surg Case Rep       Date:  2022-05-18

4.  Prediction of Unbound Ceftriaxone Concentration in Children: Simple Bioanalysis Method and Basic Mathematical Equation.

Authors:  Min Kan; Hai-Yan Shi; Zhong-Guo Sui; Wei Zhao; Bing Han; Yue-E Wu; Qian Li; Zi-Xuan Guo; Xue Li; Guo-Xiang Hao; Yi Zheng; Le-Qun Su; Xin Huang
Journal:  Antimicrob Agents Chemother       Date:  2020-12-16       Impact factor: 5.191

5.  Ceftazidime-related urinary calculi in a young boy: a case report.

Authors:  Pan Gao; Zonglai Liu; Han Yang; Ziqiu He; Zhi Zhang; Xiong Guo; Hongbo Zhang; Wei Ai; Dan Du
Journal:  J Int Med Res       Date:  2020-04       Impact factor: 1.671

6.  Ceftriaxone-associated Pseudolithiasis in Elderly People: Frequency and Risk Factors.

Authors:  Kiyoshi Hotta; Naohide Hashimura; Masaki Takatsuka; Tomoki Matsuyama; Kouichirou Nakagawa; Tsuneo Yabusako; Shuhei Hosomi; Yasuhiro Fujiwara
Journal:  Intern Med       Date:  2021-12-15       Impact factor: 1.271

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.